Evidence map›Paper›PMID 31502227›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020

Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer.

M T Genot-Klastersky, M Paesmans, L Ameye, A Kayumba, S Beauvois, T Dragan, D Van Gestel, Y Lalami, J A Klastersky

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. The supportive use of photobiomodulation on salivary glands: a narrative review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Pooled it
  2. Pooled it
  3. The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M T Genot-KlasterskyLaser Therapy Unit, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.
M PaesmansData Centre, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.
L AmeyeData Centre, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.
A KayumbaData Centre, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.
S BeauvoisDepartment of Radiation Oncology, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.
T DraganDepartment of Radiation Oncology, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.
D Van GestelDepartment of Radiation Oncology, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.
Y LalamiMedical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.
J A KlasterskyMedical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium. jean.klastersky@bordet.be.ORCID http://orcid.org/0000-0002-7941-2387

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe standard therapeutic approach for locally advanced head and neck cancer is optimal use of radiation therapy with or without concomitant chemotherapy. The most common and distressing acute complication of such therapies is oral/pharyngeal mucositis that may be associated with severe morbidity and can interfere with the planned administration of therapy.

methodsWe have identified all patients diagnosed with head/neck cancer between 2005 and 2009, having received radiotherapy with or without cisplatin-based chemotherapy. Radiotherapy consisted of intensity-modulated radiation therapy (IMRT) in all patients. In patients with grade > 2 mucositis, photobiomodulation (PBM) consisted of three sessions of low-level laser irradiation weekly, in accordance with recently published recommendations for PBM. Patients who did not receive PBM were those for whom that approach was not requested by the radiotherapists and those who declined it.

resultsTwo hundred twenty-two patients (62%) received PBM and 139 did not (39%). The patient's characteristics were equally distributed between the two groups. For overall survival, time to local recurrence, and progression-free survival, there was no statistical evidence for a difference in prognosis between patients with and without PBM. In a multivariate analysis, after adjusting for known prognostic factors, we found no statistical evidence that PBM was related to overall survival, progression-free survival, or local recurrence.

conclusionsOur results show evidence of no effect of PBM upon overall survival, time to local recurrences, and disease-free survival of patients with head and neck cancer treated with radiotherapy with/without chemotherapy.

Indexed as

Antineoplastic AgentsChemoradiotherapyCisplatinFemaleHead and Neck NeoplasmsHumansLow-Level Light TherapyMaleMiddle AgedMucositisNeoplasm Recurrence, LocalProgression-Free SurvivalRadiotherapy, Intensity-ModulatedRetrospective StudiesAntineoplastic AgentsCisplatinHead/neck cancerLaser therapyOral mucositisPhotobiomodulationPreventionRadiotherapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.